Global Antimicrobial Resistance R&D Hub Launched At Health Assembly 22/05/2018 by Damilola Adepeju for Intellectual Property Watch Leave a Comment Countries, organisations and foundations came together today alongside the annual World Health Assembly to launch the Global Antimicrobial Resistance and Development Hub (Global AMR R&D Hub).
WHO Director Dr Tedros Opens First Annual World Health Assembly With ‘Keys For Success’ 21/05/2018 by Catherine Saez, Intellectual Property Watch 1 Comment World Health Organization Director General Tedros Adhanom Ghebreyesus (“Dr Tedros”) in his first speech in his function at head of the World Health Assembly described three keys to reach the ambitious goals of the organisation. He envisioned a transformed WHO helped by a strong leadership team, called for political commitment for which he said most country leaders are ready, and advocated partnerships with a number of international health actors, including the private sector.
AI Takes Multidimensional Role In Emergency Response And Outbreaks 20/05/2018 by Damilola Adepeju for Intellectual Property Watch 1 Comment In an age where emphasis on the use of artificial intelligence (AI) for the good of humanity is increasing, last week’s AI for Good Global Summit at the International Telecommunication Union (ITU) brought leading experts together to demonstrate the multidimensionality of AI in emergency response and outbreaks, as well as in risk reduction.
Five Years After The Indian Supreme Court’s Novartis Verdict 20/05/2018 by Patralekha Chatterjee for Intellectual Property Watch 13 Comments On 1 April 2013, in a packed room inside India’s Supreme Court, a magnificent building in Indo-British architectural style, two judges delivered a verdict that impacted the national and global conversation about patents and patients. India’s apex court delivered a 112-page landmark judgement which dismissed Swiss pharma giant Novartis AG’s appeal for a patent for its life-saving cancer drug marketed under brand name Glivec in most parts of the world. The Novartis case triggered a hugely polarising discourse around the world about a key feature of India’s patent regime.
Artificial Intelligence For Good: 3 Days To Discuss AI Solutions 15/05/2018 by Catherine Saez, Intellectual Property Watch Leave a Comment The second edition of an annual global summit on “artificial intelligence for good” spearheaded by the UN International Telecommunication Union opened today. A focus of the summit is how artificial intelligence can help advance the United Nations Sustainable Development Goals. The opening statements by UN heads, including the World Health Organization, showed growing interest in new technology to help in all kinds of areas such as health and agriculture.
Trump Declares Intent To Stop Pharma Companies From ‘Gaming’ Patent System 11/05/2018 by William New, Intellectual Property Watch 2 Comments US President Trump today declared in a White House speech his intent to “take steps” to lower drug prices by stopping “gaming of regulatory and patent processes by drug makers to unfairly protect monopolies,” as well as increasing price transparency and promoting biosimilars and generics. But to do this, his administration will take on what it sees as “freeloading” on US innovation by foreign governments, and addressing “unfair” intellectual property and market access policies in trade agreements.
Brazilian Superior Court Of Justice Stops Patent Term Extension Attempts 11/05/2018 by Intellectual Property Watch 4 Comments Pedro Marcos Nunes Barbosa writes: In April 2018, the Brazilian Superior Court of Justice (STJ) ruled on a controversial patent term extension scheme, for the third time since Brazil adopted TRIPS compliant legislation in 1996. The first ruling on this topic, upheld by the STJ, was decided, unanimously, in the year 2009 (docket REsp 960.728, Justice Andrighi). In that case, a famous agrochemical multinational company sought an exotic interpretation of the impacts brought by the minimum deadline granted to a patent, since the WTO’s annex treaty imposed the uniform extension of 20 years. In other words, although the agrochemical company had obtained its exclusivity right in a pre-TRIPS context (where Brazilian Law guaranteed a 15 years property right), but unsatisfied, after the Agreement was implemented, the plaintiff requested a judicial pass for a five year extra period of competition absence.
Collective Efforts By Civil Society Groups Bar The Way To Hepatitis C Patents 10/05/2018 by Catherine Saez, Intellectual Property Watch 14 Comments Many hold the view that Gilead’s revolutionary treatment against hepatitis C (sofosbuvir) marked the beginning of a shift in position toward the high prices of medicines, as high-income countries were also faced with an untenable burden to their health systems. In a number of lower and middle-income countries, civil society organised itself to increase access to sofosbuvir for millions in need.
Truvada Case Shows Civil Society’s Success With Pre-Grant Opposition 08/05/2018 by Catherine Saez, Intellectual Property Watch 15 Comments The example of Gilead antiretroviral Truvada in Argentina and Brazil shows how civil society efforts to use patent opposition to patents it felt were unjustified were rewarded by patent withdrawal and rejection, even if the situation in Brazil might not be entirely settled.
Evergreened Patents Cause Unwarranted High Drug Prices, Hinder Growth Of Local Producers – NGOs, Thai Producers Claim 07/05/2018 by Sinfah Tunsarawuth for Intellectual Property Watch 17 Comments BANGKOK – Transnational drug manufacturers’ tactics of obtaining unmerited patent applications have unnecessarily raised healthcare costs and impeded the growth of domestic generic drug industry, costing the Thai government hundreds of millions of dollars, drug access campaigners and local producers have said.